Sökning: WFRF:(Tiensuu Janson Eva)
> (2020-2024) >
Treatment efficacy ...
-
Papantoniou, DimitriosUppsala universitet,Onkologisk endokrinologi,Ryhov Cty Hosp, Dept Oncol, Jönköping, Sweden.,Uppsala Univ, Sweden; Ryhov Cty Hosp, Sweden
(författare)
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort
- Artikel/kapitelEngelska2023
Förlag, utgivningsår, omfång ...
-
Bioscientifica,2023
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-499170
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-499170URI
-
https://doi.org/10.1530/ERC-22-0316DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-192673URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Funding Agencies|Swedish Cancer Society [18 0576]; Futurum - the Academy for Health and Care, Region Joenkoeping County
-
Small intestinal neuroendocrine tumours (Si-NET) are often studied as a uniform group. Proliferation index Ki-67 influences prognosis and determines tumour grade. We hypothesized that Si-NET grade 2 (G2) tumours, which have a higher Ki-67 than G1 tumours, might benefit less from established treatments for metastatic disease. We conducted a retrospective cohort study of 212 patients with metastatic Si-NET G2 treated in two Swedish hospitals during 20 years (2000-2019). Median cancer-specific survival on first-line somatostatin analogues (SSA) was 77 months. Median progression-free survival (PFS) was 12.4 months when SSA was given as monotherapy and 19 months for all patients receiving first-line SSA. PFS after SSA dose escalation was 6 months in patients with radiological progression. Treatment efficacies of SSA and peptide receptor radionuclide treatment (PRRT) were studied separately in patients with Ki-67 of 3-5%, 5-10% and 10-20%. For SSA, PFS was significantly shorter at higher Ki-67 levels (31, 18 and 10 months, respectively), while there was only a minor difference in PFS for PRRT (29, 25 and 25 months). Median PFS for sequential treatment with interferon-alpha (IFN alpha), everolimus and chemotherapy was 6, 5 and 9 months. IFN alpha seemed to be effective in tumours with low somatostatin-receptor expression. In conclusion, established treatments appeared effective in Si-NET G2, despite their higher proliferation index compared to G1 tumours. However, efficacy of SSA but not PRRT was reduced at higher Ki-67 levels. SSA dose escalation provided limited disease stabilization.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Grönberg, Malin,1980-Uppsala universitet,Onkologisk endokrinologi,Uppsala Univ, Sweden(Swepub:uu)magro676
(författare)
-
Thiis-Evensen, EspenOslo Univ Hosp, Rikshosp, Dept Organ Transplant, Oslo, Norway.
(författare)
-
Sorbye, HalfdanHaukeland Hosp, Dept Oncol, Bergen, Norway.;Univ Bergen, Dept Clin Med, Bergen, Norway.
(författare)
-
Landerholm, KalleLinköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Ryhov Cty Hosp, Sweden(Swepub:liu)kalla65
(författare)
-
Welin, StaffanUppsala universitet,Onkologisk endokrinologi,Uppsala Univ, Sweden(Swepub:uu)stafweli
(författare)
-
Tiensuu Janson, EvaUppsala universitet,Onkologisk endokrinologi,Uppsala Univ, Sweden(Swepub:uu)evatieja
(författare)
-
Uppsala universitetOnkologisk endokrinologi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Endocrine-Related Cancer: Bioscientifica30:31351-00881479-6821
Internetlänk
Hitta via bibliotek
Till lärosätets databas